Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011

Journal of Translational Medicine

Robin J Shattock⁴  Britta Wahren⁶  Frances Gotch^1,13  Gabriella Scarlatti^1,12  Serena Ziglio⁷  Annette Sköld³  Enas Sheik-Khalil^1,10  Elisa Saba⁵  David Reinhart⁸  Charlotte Pollard¹  Kevin Mendonca^1,11  Aneele Javed⁹  David Hallengärd⁶  Katrijn Grupping¹  Fabio Fiorino^1,11  Zelda Euler²  Marie Borggren^1,10  Nicolas Ruffin⁶ 

[1] Institute of Tropical Medicine, Nationalestraat 155, Antwerp, 2000, Belgium;Department of Experimental Immunology, Landsteiner Laboratory of Sanquin and the Academic Medical Center, University of Amsterdam, Meibergdreef, Amsterdam, 1105 AZ, The Netherlands;Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge F59, Stockholm, 141 86, Sweden;Centre for Infection, Department of Clinical Sciences, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK;AIDS Immunopathogenesis Unit, Department of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, via Olgettina, Milan, 20132, Italy;Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Nobels väg 16, Stockholm, 171 77, Sweden;Department of Life and Reproduction Sciences, University of Verona, Strada Le Grazie, Verona, 37134, Italy;Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 11, 1190, Vienna, Austria;Leibniz Institute for Primate Research, German Primate Centre, Kellnerweg, Goettingen, 37077, Germany;Department of Laboratory Medicine, Lund University, Sölvegatan, Lund, 223 62, Sweden;Department of Biotechnology, University of Siena, Viale Bracci, Siena, 53100, Italy;Viral Evolution and Transmission Unit, Department of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Via Olgettina, Milan, 20132, Italy;Department of Immunology, Imperial College London, Fulham Road, London, SW10 9NH, UK

关键词: PrEP;    Microbicide;    Vaccine;    HIV;   

Others  :  1205937
DOI  :  10.1186/1479-5876-10-144

 received in 2012-05-14, accepted in 2012-06-28,  发布年份 2012

【 摘 要 】

Europrise is a Network of Excellence supported by the European Commission within the 6th Framework programme from 2007 to 2012. The Network has involved over 50 institutions from 13 European countries together with 3 industrial partners and 6 African countries. The Network encompasses an integrated program of research, training, dissemination and advocacy within the field of HIV vaccines and microbicides. A central and timely theme of the Network is the development of the unique concept of co-usage of vaccines and microbicides. Training of PhD students has been a major task, and some of these post-graduate students have here summarized novel ideas emanating from presentations at the last annual Europrise meeting in Prague. The latest data and ideas concerning HIV vaccine and microbicide studies are included in this review; these studies are so recent that the majority have yet to be published. Data were presented and discussed concerning novel immunisation strategies; microbicides and PrEP (alone and in combination with vaccines); mucosal transmission of HIV/SIV; mucosal vaccination; novel adjuvants; neutralizing antibodies; innate immune responses; HIV/SIV pathogenesis and disease progression; new methods and reagents. These – necessarily overlapping topics - are comprehensively summarised by the Europrise students in the context of other recent exciting data.

【 授权许可】

   
2012 Ruffin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Brinckmann S, da Costa K, van Gils MJ, Hallengard D, Klein K, Madeira L, Mainetti L, Palma P, Raue K, Reinhart D, et al.: Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. J Transl Med 2011, 9:40. BioMed Central Full Text
• [2]Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, De Haes W, Dieltjens T, Dispinseri S, Grupping K, Hallengard D, et al.: Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference. J Transl Med 2010, 8:72. BioMed Central Full Text
• [3]Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
• [4]Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
• [5]Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, et al.: Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012. Epub ahead of print
• [6]Garcia F, Bernaldo de Quiros JC, Gomez CE, Perdiguero B, Najera JL, Jimenez V, Garcia-Arriaza J, Guardo AC, Perez I, Diaz-Brito V, et al.: Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). Vaccine 2011, 29:8309-8316.
• [7]Gomez CE, Najera JL, Perdiguero B, Garcia-Arriaza J, Sorzano CO, Jimenez V, Gonzalez-Sanz R, Jimenez JL, Munoz-Fernandez MA, Lopez Bernaldo de Quiros JC, et al.: The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol 2011, 85:11468-11478.
• [8]Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, et al.: Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198:1482-1490.
• [9]Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, et al.: Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011, 29:8417-8428.
• [10]Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, et al.: A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007, 46:48-55.
• [11]Letourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael AJ, Hanke T: Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007, 2:e984.
• [12]Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, Ammendola V, Ljungberg K, Borthwick N, Im EJ, et al.: Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 2010, 40:1973-1984.
• [13]Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, et al.: Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998, 72:7992-8001.
• [14]Buonaguro L, Tagliamonte M, Visciano ML, Andersen H, Lewis M, Pal R, Tornesello ML, Schroeder U, Hinkula J, Wahren B, Buonaguro FM: Immunogenicity of HIV virus-like particles in Rhesus Macaques by intra-nasal administration. Clin Vaccine Immunol 2012. Epub ahead of print
• [15]Wang Y, Whittall T, Rahman D, Bunnik EM, Vaughan R, Scholler J, Bergmeier LA, Montefiori D, Singh M, Schuitemaker H, Lehner T: The role of innate APOBEC3G and adaptive aid immune responses in HLA-HIV/SIV immunized SHIV infected Macaques. PLoS One 2012, 7:e34433.
• [16]Liu MA: Immunologic basis of vaccine vectors. Immunity 2010, 33:504-515.
• [17]Mascola JR, Montefiori DC: The role of antibodies in HIV vaccines. Annu Rev Immunol 2010, 28:413-444.
• [18]Negri DR, Michelini Z, Baroncelli S, Spada M, Vendetti S, Bona R, Leone P, Klotman ME, Cara A: Nonintegrating lentiviral vector-based vaccine efficiently induces functional and persistent CD8+ T cell responses in mice. J Biomed Biotechnol 2010, 2010:534501.
• [19]Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M: SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474:654-657.
• [20]Hallengard D, Haller BK, Maltais AK, Gelius E, Nihlmark K, Wahren B, Brave A: Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clin Vaccine Immunol 2011, 18:1577-1581.
• [21]Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, et al.: Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 2011, 12:67. BioMed Central Full Text
• [22]no author listed: Early end for FEM-PrEP HIV prevention trial. AIDS Patient Care STDS 2011, 25:383.
• [23]Stolte-Leeb N, Loddo R, Antimisiaris S, Schultheiss T, Sauermann U, Franz M, Mourtas S, Parsy C, Storer R, La Colla P, Stahl-Hennig C: Topical Nonnucleoside Reverse Transcriptase Inhibitor MC 1220 Partially Prevents Vaginal RT-SHIV Infection of Macaques. Aids Research and Human Retroviruses 2011, 27:933-943.
• [24]Wijesundara DK, Jackson RJ, Ramshaw IA, Ranasinghe C: Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol Cell Biol 2011, 89:367-374.
• [25]Kaufman DR, Liu J, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH: Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J Immunol 2008, 181:4188-4198.
• [26]Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, et al.: Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006, 80:3732-3742.
• [27]Ranasinghe C, Ramshaw IA: Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity. Eur J Immunol 2009, 39:1819-1830.
• [28]Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, et al.: A whole-genome association study of major determinants for host control of HIV-1. Science 2007, 317:944-947.
• [29]van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, van't Wout AB, Schuitemaker H: Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009, 23:19-28.
• [30]Reinhart D, Weik R, Kunert R: Recombinant IgA production: single step affinity purification using camelid ligands and product characterization. J Immunol Methods 2012, 378:95-101.
• [31]Borrow P, Shattock RJ, Vyakarnam A: Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology 2010, 7:84. BioMed Central Full Text
• [32]Coma G, Pena R, Blanco J, Rosell A, Borras FE, Este JA, Clotet B, Ruiz L, Parkhouse RM, Bofill M: Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10. Clin Exp Immunol 2006, 145:535-544.
• [33]Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, Mothes W, Poli G, Luban J, Vicenzi E: TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol 2011, 85:5183-5196.
• [34]Shattock RJ, Warren M, McCormack S, Hankins CA: AIDS. Turning the tide against HIV. Science 2011, 333:42-43.